LCTX Lineage Cell Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: LCTX

Price (delayed)

$0.9567

Market cap

$241.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.14

Enterprise value

$206.9M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 30

BioTime is a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. BioTime’s programs ...

Highlights
The company's net income rose by 50% QoQ and by 21% YoY
LCTX's EPS has soared by 50% since the previous quarter and by 22% year-on-year
Lineage Cell Therapeutics's quick ratio has surged by 63% YoY but it has decreased by 3.2% QoQ
The gross profit has grown by 22% YoY but it has contracted by 11% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.lineagecell.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of LCTX

LCTX stock price

How has the Lineage Cell Therapeutics stock price performed over time
Intraday
-8.01%
1 week
-10.59%
1 month
-11.42%
1 year
-39.83%
YTD
-42.71%
QTD
-26.97%

Financial performance

How have Lineage Cell Therapeutics's revenue and profit performed over time
Revenue
$13.08M
Gross profit
$13.01M
Operating income
-$26.85M
Net income
-$32.26M
Gross margin
99.5%
Net margin
-246.6%
The company's net income rose by 50% QoQ and by 21% YoY
The net margin has grown by 43% from the previous quarter and by 34% YoY
LCTX's operating margin is up by 36% year-on-year and by 20% since the previous quarter
The operating income has increased by 29% since the previous quarter and by 24% year-on-year

Price vs fundamentals

How does LCTX's price correlate with its fundamentals

Growth

What is Lineage Cell Therapeutics's growth rate over time

Valuation

What is Lineage Cell Therapeutics stock price valuation
P/E
N/A
P/B
3.92
P/S
18.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.81
LCTX's EPS has soared by 50% since the previous quarter and by 22% year-on-year
LCTX's P/B is 56% below its last 4 quarters average of 9.7 and 3.2% below its 5-year quarterly average of 4.4
LCTX's equity is up by 26% YoY and by 13% QoQ
LCTX's price to sales (P/S) is 36% less than its 5-year quarterly average of 30.8 and 30% less than its last 4 quarters average of 28.3
The revenue has grown by 20% YoY but it has contracted by 11% from the previous quarter

Efficiency

How efficient is Lineage Cell Therapeutics business performance
Lineage Cell Therapeutics's ROIC has soared by 65% from the previous quarter
LCTX's return on equity has surged by 53% since the previous quarter but it is down by 18% year-on-year
Lineage Cell Therapeutics's ROA has soared by 52% from the previous quarter and by 22% YoY
LCTX's ROS is up by 39% since the previous quarter and by 23% year-on-year

Dividends

What is LCTX's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Lineage Cell Therapeutics financials performed over time
LCTX's total assets is 129% greater than its total liabilities
Lineage Cell Therapeutics's quick ratio has surged by 63% YoY but it has decreased by 3.2% QoQ
The current ratio has surged by 62% year-on-year but it has declined by 4.1% since the previous quarter
The debt is 96% less than the equity
LCTX's equity is up by 26% YoY and by 13% QoQ
The debt has grown by 7% YoY but it has contracted by 4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.